Faron Pharmaceuticals Limited is a clinical-stage biopharmaceutical company based in Finland and the United States, with a focus on developing bexmarilimab, a first-in-class, humanized antibody that binds the Clever-1 target on myeloid cells and macrophages.
Clever-1 is an immunosuppressive receptor that promotes tumour growth and metastases when expressed on macrophages
Bexmarilimab primes the tumour microenvironment for optimal antitumour immune responses, in both hematological malignancies and solid tumours.